← Leaderboards
Lawrence Mahan
Madeleine Pharmaceuticals, Inc.
$2,962,343
Attributed
$3,927,918
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2016–22$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,927,918 · 1
By mechanism
R44$3,927,918 · 1
Top collaborators
- Marc S Penn3 shared
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseGlomerular Filtration RateDistalDiureticsDyspneaFundingCreatinine Clearance MeasurementDinoprostoneClinical ResearchDiuresisDrug DevelopmentDuct (Organ) StructureExcretory FunctionFamilyAcuteClinical TrialsAngiotensin-Converting Enzyme InhibitorsDiagnosisCessation Of LifeChemistryAtp PhosphohydrolaseClinicCommercializationHealth Care Economics
Grant awards (4)
A Phase 2a Clinical Study of a Cardiac Hormone for the Outpatient Treatment of Worsening Heart Failure$1
R44 · FY2022 · HL · contact PI
A Phase 2a Clinical Study of a Cardiac Hormone for the Outpatient Treatment of Worsening Heart Failure$1,044,010
R44 · FY2021 · HL · contact PI
A Phase 2a Clinical Study of a Cardiac Hormone for the Outpatient Treatment of Worsening Heart Failure$887,140
R44 · FY2020 · HL · contact PI
Development of a novel drug treatment for decompensated heart failure.$1,996,767
R44 · FY2016 · HL · contact PI